Back to results
US 2024/0285613 A1Published application
Treatment for autoimmune diseases
AssigneeLDN Pharma Limited
InventorsWai Liu, Ian Thompson, Francis Hood
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeLDN Pharma Limited
InventorsWai Liu, Ian Thompson, Francis Hood
Estimating the term…
A pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, for use in the treatment of an autoimmune disease within a subject, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is to be administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is to be administered a therapeutically effective amount of a cannabinoid, flavonoid or terpene in a second treatment phase, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is to be administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.
A method of treating an autoimmune disease within a subject, comprising administering a pharmaceutical composition comprising naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, wherein a therapeutically effective amount of the naltrexone or metabolite thereof or analogue of either is administered to the subject in a first treatment phase, wherein after the first treatment phase the subject is administered a therapeutically effective amount of a cannabinoid, flavonoid or terpene in a second treatment phase, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is to be administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.
A method of treating an autoimmune disease within a subject, wherein said subject is characterized in having undergone a first treatment phase during which the subject is administered a therapeutically effective amount of naltrexone or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, and wherein following the first treatment phase a therapeutically effective amount of a cannabinoid, flavonoid or terpene is administered to the subject, and wherein an agonist of a 5-hydroxytryptamine (5-HT) receptor is administered to the subject either simultaneously, sequentially or separately with the naltrexone, the metabolite or analogue.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
23-24. (canceled)
Dependencies are inferred from the claim text.